title: Outcome of HLA-matched related allogeneic hematopoietic stem cell transplantation for patients with acute leukemia in first complete remission treated in Eastern European centers. Better results in recent years.
abstract: The goal of this study was to analyze results and to determine factors affecting outcome of HLA-matched hematopoetic stem cells transplantation (MRD-HSCT) for patients with acute leukemia transplanted in first complete remission in Eastern European countries. Six hundred forty HSCT were performed between 1990 and 2006 for adults with acute myeloid (n = 459) and lymphoblastic (n = 181) leukemia. Two-year leukemia-free survival (LFS), nonrelapse mortality (NRM), and relapse incidence were 58 +/- 2%, 19 +/- 2%, and 23 +/- 2%, respectively. The cumulative incidence of NRM decreased from 22 +/- 2% for patients treated between 1990 and 2002 to 15 +/- 3% for transplantations performed between 2003 and 2006 (p = 0.02), despite increasing recipient age. In a multivariate analysis, time of HSCT affected both NRM and LFS. Among other prognostic factors, the use of TBI decreased relapse incidence and increased the LFS rate. We conclude that results of MRD-HSCT for acute leukemia in Eastern Europe improved over time as a consequence of decreased NRM. The use of TBI containing regimens appears advantagous.
authors.affiliation: Department of Clinical Oncology, Comprehensive Cancer Center, Maria Sklodowska-Curie Memorial Institute Branch Gliwice, Wybrzeze Armii Krajowej 15, 44-101, Gliwice, Poland. sgiebel@poczta.onet.pl
authors.forename: Sebastian
authors.initials: S
authors.lastname: Giebel
authors.forename: Myriam
authors.initials: M
authors.lastname: Labopin
authors.forename: Jerzy
authors.initials: J
authors.lastname: Holowiecki
authors.forename: Boris
authors.initials: B
authors.lastname: Labar
authors.forename: Mieczyslaw
authors.initials: M
authors.lastname: Komarnicki
authors.forename: Vladimir
authors.initials: V
authors.lastname: Koza
authors.forename: Tamas
authors.initials: T
authors.lastname: Masszi
authors.forename: Martin
authors.initials: M
authors.lastname: Mistrik
authors.forename: Andrzej
authors.initials: A
authors.lastname: Lange
authors.forename: Andrzej
authors.initials: A
authors.lastname: Hellmann
authors.forename: Antonin
authors.initials: A
authors.lastname: Vitek
authors.forename: Joze
authors.initials: J
authors.lastname: Pretnar
authors.forename: Jiri
authors.initials: J
authors.lastname: Mayer
authors.forename: Piotr
authors.initials: P
authors.lastname: Rzepecki
authors.forename: Karel
authors.initials: K
authors.lastname: Indrak
authors.forename: Wieslaw
authors.initials: W
authors.lastname: Wiktor-Jedrzejczak
authors.forename: Jerzy
authors.initials: J
authors.lastname: Wojnar
authors.forename: Malgorzata
authors.initials: M
authors.lastname: Krawczyk-Kulis
authors.forename: Slawomira
authors.initials: S
authors.lastname: Kyrcz-Krzemien
authors.forename: Vanderson
authors.initials: V
authors.lastname: Rocha
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D005061:Europe, Eastern; D006680:HLA Antigens; D018380:Hematopoietic Stem Cell Transplantation / Q000379:methods* / Q000401:mortality; D006648:Histocompatibility; D006801:Humans; D007938:Leukemia / Q000175:diagnosis* / Q000401:mortality / Q000628:therapy*; D015470:Leukemia, Myeloid, Acute / Q000175:diagnosis / Q000401:mortality / Q000628:therapy; D008875:Middle Aged; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000175:diagnosis / Q000401:mortality / Q000628:therapy; D011379:Prognosis; D012008:Recurrence; D012074:Remission Induction; D012189:Retrospective Studies; D016019:Survival Analysis; D013997:Time Factors; D014184:Transplantation, Homologous; D016896:Treatment Outcome; D014916:Whole-Body Irradiation; D055815:Young Adult
chemical_list: D006680:HLA Antigens